GI Dynamics, Inc. - ASX Announcement

FOR IMMEDIATE RELEASE GI Dynamics Announces EndoBarrier® Data to be Presented at The American Diabetes Association's 74th Scientific Sessions

LEXINGTON, Massachusetts, United States and SYDNEY, Australia - 9 June 2014 - GI Dynamics, Inc. (ASX: GID), a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced that new data on EndoBarrier® will be presented during three poster presentations at The American Diabetes Association's (ADA) 74th Scientific Sessions, taking place June 13-17, 2014, in San Francisco.

The schedule for the ADA presentations is as follows:

Date & Time: Saturday, June 14 from 11:30-1:30 p.m. PT Session: Saturday General Poster Session Title: Duodenal-Jejunal Bypass Liner Increases Bile Acids Levels in Patients with Severe Obesity and Type 2 Diabetes Mellitus Abstract Number: 1906-P Location: Hall D Presenter: Alex Escalona, M.D., assistant professor of surgery, Department of Digestive Surgery, Pontificia Universidad Católica de Chile, Santiago, Chile Date & Time: Sunday, June 15 at 12-2 p.m. PT Session: Sunday General Poster Session Title: Endoscopic, Duodenal-Jejunal Bypass Liner Exerts Robust Improvement in Glycemia and

Body Weight in Obese Patients with Type 2 Diabetes

Abstract Number: 1104 - P Location: Hall D Presenter: Dennis Kim, M.D., MBA, principal, MetaCon, Inc. Date & Time: Sunday, June 15 at 12-2 p.m. PT Session: Sunday General Poster Session Title: The Acute Effect Of EndoBarrier Treatment On Glucose Homeostasis In Obese Uncontrolled Diabetic Subjects Abstract Number: 879-P Location: Hall D Presenter: Gabriella Lieberman, M.D., Institute of Endocrinology, Sheba Medical Center, Tel Aviv, Israel

www.gidynamics.com

US OFFICE & HEADQUARTERS: 25 Hartwell Avenue, Lexington MA 02421 T +1 (781) 357-3300 F +1 (781) 357-3301

EUROPEAN OFFICE: De Tweeling 20-22 's-Hertogenbosch 5215 MC, THE NETHERLANDS T: + 31 13 547 9300

AUSTRALIAN OFFICE: Level 8, 17-19 Bridge Street, Sydney, NSW 2000 T +61 2 9325 9046

GI Dynamics, Inc., is a corporation incorporated in Delaware, USA, whose stockholders have limited liability. ARBN 151 239 388

GI Dynamics, Inc. - ASX Announcement Page 2

About GI Dynamics

GI Dynamics, Inc. (ASX: GID) is the developer of EndoBarrier®, the first endoscopically-delivered device therapy approved for the treatment of type 2 diabetes and/or obesity. EndoBarrier is approved and commercially available in multiple countries outside the U.S.
EndoBarrier is not approved for sale in the U.S. and is limited by federal law to investigational use only in the United States. GI
Dynamics is conducting a pivotal clinical trial of EndoBarrier in the U.S. for the treatment of patients who have uncontrolled type 2 diabetes and are obese. Founded in 2003, GI Dynamics is headquartered in Lexington, Massachusetts. For more information, please visit www.gidynamics.com.

Forward-Looking Statements

This announcement contains forward-looking statements concerning: our development and commercialization plans; our potential
revenues, costs, profitability and financial performance; our ability to obtain reimbursement for our products; our clinical trials, and associated regulatory submissions and approvals; the number and location of commercial centres offering the EndoBarrier®; and our intellectual property position. These forward-looking statements are based on the current estimates and expectations of future events by the management of GI Dynamics, Inc. as of the date of this announcement and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those indicated in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks associated with the possibility that clinical trials will not be successful or confirm earlier results; risks associated with obtaining funding from third parties; risks relating to the timing and costs of clinical
trials, results of clinical trials, the timing of regulatory submissions, the timing and receipt of regulatory approvals, the timing and amount of other expenses; execution risks; competition; risks related to market acceptance of products; intellectual property risks; and assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches, future financial results and other factors. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.

Investor Enquiries: Media Enquiries:

United States

Robert Crane, Chief Financial Officer

+1 (781) 357-3250

United States/Europe:

Dan Budwick, Pure Communications Inc.

+1 (973) 271-6085

Australia

David Allen or John Granger, Hawkesbury Partners

Pty Limited

+61 2 9325 9046

Australia

Angela Ceberano, Flourish PR

+61 3 9092 8445

www.gidynamics.com

US OFFICE & HEADQUARTERS: 25 Hartwell Avenue, Lexington MA 02421 T +1 (781) 357-3300 F +1 (781) 357-3301

EUROPEAN OFFICE: De Tweeling 20-22 's-Hertogenbosch 5215 MC, THE NETHERLANDS T: + 31 13 547 9300

AUSTRALIAN OFFICE: Level 8, 17-19 Bridge Street, Sydney, NSW 2000 T +61 2 9325 9046

GI Dynamics, Inc., is a corporation incorporated in Delaware, USA, whose stockholders have limited liability. ARBN 151 239 388

distributed by